FTSE MIB
33.768,44 +139,23 (+0,41%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,94 +0,83 (+1,06%) Bitcoin EUR
60.647,68 +1.599,97 (+2,71%)
Intra-Cellular Therapies, Inc. (ITCI)
Dopo ore:
| Chiusura precedente | 70,34 |
| Aperto | 71,07 |
| Denaro | 68,74 x 200 |
| Lettera | 68,86 x 200 |
| Min-Max giorno | 68,48 - 71,35 |
| Intervallo di 52 settimane | 45,50 - 84,89 |
| Volume | |
| Media Volume | 983.360 |
| Capitalizzazione | 7,263B |
| Beta (5 anni mensile) | 1,01 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,46 |
| Prossima data utili | 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 91,91 |
GlobeNewswireIntra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:15 p.m. ET. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company
- GlobeNewswire
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 12:55 p.m. ET. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Comp
- GlobeNewswire
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's websit
